So, our experimental approach showed that dermcidin might regulate other parameters which are involved in cardiac diseases and if we aware of DCN-2 regulated IR (HOMA score analysis), NO, HbA1c and cTroponinT level, then our experiment might be helpful for the prostate cancer patients (patients are already in the IR state and prone to AIHD development) to whom different types of cardiotoxic therapy would be exposed, because the timing and dosages of therapeutic agents then would be exposed in a controlled manner and cardiotoxicity might be decreased at least. The gene discussed is DCD; the disease is prostate cancer.